The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis

Surgery Today

Volumn 46, Issue 8, 2016, Pages 939-949

  Yasueda, Asuka ^a   Mizushima, Tsunekazu ^a   Nezu, Riichiro ^b   Sumi, Ryoko ^c   Tanaka, Mamoru ^d   Nishimura, Junichi ^a   Kai, Yasuyuki ^e   Hirota, Masaki ^f   Osawa, Hideki ^a   Nakajima, Kiyokazu ^c   Mori, Masaki ^a   Ito, Toshinori ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Nishinomiya Municipal Central Hospital   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d Miyarisan Pharmaceutical Co   (Japan)

^e Hanwa Sumiyoshi General Hospital   (Japan)

^f OSAKA ROSAI HOSPITAL   (Japan)

Author keywords

Clostridium butyricum MIYAIRI; IPAA; Pouchitis; Probiotics; Ulcerative colitis

Indexed keywords

PLACEBO; PROBIOTIC AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL ARTICLE; CLOSTRIDIUM BUTYRICUM; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FECES ANALYSIS; FECES MICROFLORA; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; ILEITIS; ILEOANAL ANASTOMOSIS; ILEUM POUCH; INTESTINE FLORA; MALE; MIDDLE AGED; NONHUMAN; POUCHITIS FREE SURVIVAL; PROCTOCOLECTOMY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; ULCERATIVE COLITIS; ANASTOMOSIS; COLITIS, ULCERATIVE; COLOSTOMY BAG; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; POSTOPERATIVE COMPLICATIONS; POUCHITIS;

ADMINISTRATION, ORAL; ADULT; ANASTOMOSIS, SURGICAL; CLOSTRIDIUM BUTYRICUM; COLITIS, ULCERATIVE; COLONIC POUCHES; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; POUCHITIS; PROBIOTICS; PROCTOCOLECTOMY, RESTORATIVE;

EID: 84945550161     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-015-1261-9     Document Type: Article

References (45)

1. Glocker E-O, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, Perro M, Diestelhorst J, Allroth A, Murugan D, Hätscher N, Pfeifer D, Sykora K-W, Sauer M, Kreipe H, Lacher M, Nustede R, Woellner C, Baumann U, Salzer U, Koletzko S, Shah N, Segal AW, Sauerbrey A, Buderus S, Snapper SB, Grimbacher B, Klein C. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361:2033–45.
2. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(Suppl 5):V1–16.
3. Andoh A, Sakata S, Koizumi Y, Mitsuyama K, Fujiyama Y, Benno Y. Terminal restriction fragment length polymorphism analysis of the diversity of fecal microbiota in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:955–62.
4. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJS, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–76.
5. Hata K, Kazama S, Nozawa H, et al. Laparoscopic surgery for ulcerative colitis: a review of the literature. Surg Today. 2015;45(8):933–8.
6. Zella GC, Hait EJ, Glavan T, Gevers D, Ward DV, Kitts CL, Korzenik JR. Distinct microbiome in pouchitis compared to healthy pouches in ulcerative colitis and familial adenomatous polyposis. Inflamm Bowel Dis. 2011;17:1092–100.
7. Sartor RB. Probiotics in chronic pouchitis: restoring luminal microbial balance. Gastroenterology. 2000;119:584–7.
8. Turina M, Pennington CJ, Kimberling J, Stromberg AJ, Petras RE, Galandiuk S. Chronic pouchitis after ileal pouch-anal anastomosis for ulcerative colitis: effect on quality of life. J Gastrointest Surg. 2006;10:600–6.
9. Uchino M, Ikeuchi H, Matsuoka H, Bando T, Takesue Y, Tomita N. Clinical features and management of pouchitis in japanese ulcerative colitis patients. Surg Today. 2013;43:1049–57.
10. Hashimoto T, Itabashi M, Ogawa S, Hirosawa T, Bamba Y, Kaji S, Ubukata M, Nakao S, Kameoka S. A treatment strategy for preventing pouchitis as a postoperative complication of ulcerative colitis: the significance of the management of cuffitis. Surg Today. 2014;44:1730–4.
11. Jewell DP, Mortensen NJ, Steinhart AH, Pemberton JH, Warren BF. Challenges in inflammatory bowel disease. 2nd ed. Oxford: Blackwell Publishing; 2006. p. 170.
12. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA. Once daily high dose probiotic therapy (vsl#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108–14.
13. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:305–9.
14. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003;124:1202–9.
15. Laake KO, Bjorneklett A, Aamodt G, Aabakken L, Jacobsen M, Bakka A, Vatn MH. Outcome of four weeks’ intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a j-configurated ileal-pouch-anal-anastomosis in ulcerative colitis. Scand J Gastroenterol. 2005;40:43–51.
16. Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Phillips SF. Pouchitis after ileal pouch-anal anastomosis: a pouchitis disease activity index. Mayo Clin Proc. 1994;69:409–15.
17. Shen B, Achkar JP, Connor JT, Ormsby AH, Remzi FH, Bevins CL, Brzezinski A, Bambrick ML, Fazio VW, Lashner BA. Modified pouchitis disease activity index: a simplified approach to the diagnosis of pouchitis. Dis Colon Rectum. 2003;46:748–53.
18. Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O’Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D. Development of the national cancer institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9):1–11.
19. Andoh A, Kuzuoka H, Tsujikawa T, Nakamura S, Hirai F, Suzuki Y, Matsui T, Fujiyama Y, Matsumoto T. Multicenter analysis of fecal microbiota profiles in japanese patients with Crohn’s disease. J Gastroenterol. 2012;47:1298–307.
20. Kumagai H, Maisawa S, Tanaka M, Takahashi M, Takasago Y, Nishijima A, Watanabe S. Intestinal microbiota and secretory immunoglobulin a in feces of exclusively breast-fed infants with blood-streaked stools. Microbiol Immunol. 2012;56:657–63.
21. Andoh A, Imaeda H, Aomatsu T, Inatomi O, Bamba S, Sasaki M, Saito Y, Tsujikawa T, Fujiyama Y. Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn’s disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol. 2011;46:479–86.
22. Meagher AP, Farouk R, Dozois RR, Kelly KA, Pemberton JH. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg. 1998;85:800–3.
23. Ohigashi S, Hoshino Y, Ohde S, Onodera H. Functional outcome, quality of life, and efficacy of probiotics in postoperative patients with colorectal cancer. Surg Today. 2011;41:1200–6.
24. Hayashi A, Sato T, Kamada N, Mikami Y, Matsuoka K, Hisamatsu T, Hibi T, Roers A, Yagita H, Ohteki T, Yoshimura A, Kanai T. A single strain of clostridium butyricum induces intestinal il-10-producing macrophages to suppress acute experimental colitis in mice. Cell Host Microbe. 2013;13:711–22.
25. Takahashi M, Chang D, Dong X, Bao Y. The difference and the improvement effects of intestinal flora between irritable bowel syndrome patients and healthy volunteer using Clostridium butyricum MIYAIRI 588 [in Japanese]. J Jpn Soc Clin Studies Intest Microflora. 2001;3(1):45–7.
26. Gonzalez-Rodriguez I, Gaspar P, Sanchez B, Gueimonde M, Margolles A, Neves AR. Catabolism of glucose and lactose in Bifidobacterium animalis subsp. lactis, studied by 13c nuclear magnetic resonance. Appl Environ Microbiol. 2013;79:7628–38.
27. Roger LC, Costabile A, Holland DT, Hoyles L, McCartney AL. Examination of faecal bifidobacterium populations in breast- and formula-fed infants during the first 18 months of life. Microbiology (Reading, England). 2010;156:3329–41.
28. Seo M, Inoue I, Tanaka M, Matsuda N, Nakano T, Awata T, Katayama S, Alpers DH, Komoda T. Clostridium butyricum miyairi 588 improves high-fat diet-induced non-alcoholic fatty liver disease in rats. Dig Dis Sci. 2013;58:3534–44.
29. Hulten L. Proctocolectomy and ileostomy to pouch surgery for ulcerative colitis. World J Surg. 1998;22:335–41.
30. Martinez-Medina M, Garcia-Gil LJ. Escherichia coli in chronic inflammatory bowel diseases: an update on adherent invasive Escherichia coli pathogenicity. World J Gastrointest Pathophysiol. 2014;5:213–27.
31. De la Fuente M, Franchi L, Araya D, Diaz-Jimenez D, Olivares M, Alvarez-Lobos M, Golenbock D, Gonzalez MJ, Lopez-Kostner F, Quera R, Nunez G, Vidal R, Hermoso MA. Escherichia coli isolates from inflammatory bowel diseases patients survive in macrophages and activate nlrp3 inflammasome. Int J Med Microbiol. 2014;304:384–92.
32. Pilarczyk-Zurek M, Chmielarczyk A, Gosiewski T, Tomusiak A, Adamski P, Zwolinska-Wcislo M, Mach T, Heczko PB, Strus M. Possible role of escherichia coli in propagation and perpetuation of chronic inflammation in ulcerative colitis. BMC Gastroenterol. 2013;13:61.
33. Parsi MA, Shen B, Achkar JP, Remzi FF, Goldblum JR, Boone J, Lin D, Connor JT, Fazio VW, Lashner BA. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology. 2004;126:1280–6.
34. Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett. 2009;294:1–8.
35. Gonzalez-Pajuelo M, Andrade JC, Vasconcelos I. Production of 1,3-propanediol by clostridium butyricum vpi 3266 using a synthetic medium and raw glycerol. J Ind Microbiol Biotechnol. 2004;31:442–6.
36. Courtois F, Seidman EG, Delvin E, Asselin C, Bernotti S, Ledoux M, Levy E. Membrane peroxidation by lipopolysaccharide and iron-ascorbate adversely affects caco-2 cell function: beneficial role of butyric acid. Am J Clin Nutr. 2003;77:744–50.
37. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, Nakanishi Y, Uetake C, Kato K, Kato T, Takahashi M, Fukuda NN, Murakami S, Miyauchi E, Hino S, Atarashi K, Onawa S, Fujimura Y, Lockett T, Clarke JM, Topping DL, Tomita M, Hori S, Ohara O, Morita T, Koseki H, Kikuchi J, Honda K, Hase K, Ohno H. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory t cells. Nature. 2013;504:446–50.
38. Chen WX, Ren LH, Shi RH. Enteric microbiota leads to new therapeutic strategies for ulcerative colitis. World J Gastroenterol. 2014;20:15657–63.
39. Kumari R, Ahuja V, Paul J. Fluctuations in butyrate-producing bacteria in ulcerative colitis patients of north india. World J Gastroenterol. 2013;19:3404–14.
40. Luhrs H, Gerke T, Muller JG, Melcher R, Schauber J, Boxberge F, Scheppach W, Menzel T. Butyrate inhibits nf-kappab activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol. 2002;37:458–66.
41. Luhrs H, Kudlich T, Neumann M, Schauber J, Melcher R, Gostner A, Scheppach W, Menzel TP. Butyrate-enhanced tnfalpha-induced apoptosis is associated with inhibition of nf-kappab. Anticancer Res. 2002;22:1561–8.
42. Roger T, David J, Glauser MP, Calandra T. Mif regulates innate immune responses through modulation of toll-like receptor 4. Nature. 2001;414:920–4.
43. Celada A, Borras FE, Soler C, Lloberas J, Klemsz M, van Beveren C, McKercher S, Maki RA. The transcription factor pu.1 is involved in macrophage proliferation. J Exp Med. 1996;184:61–9.
44. Isono A, Katsuno T, Sato T, Nakagawa T, Kato Y, Sato N, Seo G, Suzuki Y, Saito Y. Clostridium butyricum to-a culture supernatant downregulates tlr4 in human colonic epithelial cells. Dig Dis Sci. 2007;52:2963–71.
45. Toiyama Y, Araki T, Yoshiyama S, Hiro J, Miki C, Kusunoki M. The expression patterns of toll-like receptors in the ileal pouch mucosa of postoperative ulcerative colitis patients. Surg Today. 2006;36:287–90.